Loxo Oncology Inc
Most Recent
Analyst Recommendations for Ignyta and Its Peers in January 2018
Of the four analysts covering Ignyta in January 2018, all of them have given the stock a “hold” rating. The mean rating for the stock is 3.0 with a target price of $28.
Array BioPharma Missed Sales Estimates for Q4 2018
Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.
A Close Look at Ignyta’s Licensing Agreement
Ignyta (RXDX) entered into a licensing agreement with Nerviano Medical Sciences in which Ignyta has exclusive global rights to develop and commercialize entrectinib.
Inside Ignyta’s Financial Performance
Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.
Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?
In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.
Eli Lilly and Loxo: A Robust Oncology Pipeline for Future Years
Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.
Loxo Oncology Is Expected to Boost Eli Lilly’s Revenue in 2019
Eli Lilly and Company (LLY) expects its Loxo Oncology (LOXO) acquisition to become revenue accretive starting in 2019.
What Are Analysts Recommending for Eli Lilly and Loxo Oncology?
Eli Lilly and Company (LLY) has entered into an agreement to acquire Loxo Oncology (LOXO) for a net consideration of $7.2 billion.
Why Loxo Oncology Has Surged More than 65% Today
Earlier today, American pharmaceutical giant Eli Lilly and Company (LLY) announced its acquisition of Loxo Oncology (LOXO).
Why Endocyte’s Stock Price Rose 11.4% Yesterday
Today, Endocyte stock is trading at $19.16, which reflects ~1.43% growth from yesterday’s closing price of $18.89. Here’s why.
Analyst Recommendations for Exelixis in August
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.
Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18
On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63.
Array BioPharma’s Financial Performance
The total revenues of Array BioPharma (ARRY) decreased from $39.2 million in 1Q17 to $29.7 million in 1Q18.
Array BioPharma’s ARRY-382 and ARRY-797
Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.
Taking Stock of Arrowhead Pharmaceuticals’ Financial Performance
In 2017, Arrowhead Pharmaceuticals (ARWR) generated revenue of $31.4 million compared to $158,000 in 2016. This increase was attributable to the upfront payments Arrowhead received from Amgen.
What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.
Analysts’ Recommendations for Arrowhead and Its Peers
Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them.
